Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis
Launched by GELB, ARTHUR F., M.D. · Feb 11, 2019
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to find out if there are small airway problems in children and adults with cystic fibrosis that are not usually detected during standard breathing tests. Even if these tests show normal results, the study aims to identify issues that could affect lung function. This research will help doctors understand cystic fibrosis better and improve care for patients.
To participate, you need to be a child or adult with cystic fibrosis who has normal results on routine breathing tests, which include measurements like FEV1, FVC, and the ratio of these two (FEV1/FVC%). Unfortunately, if you have any abnormal results on these tests, you won't be eligible for the study. If you join, you’ll help researchers learn more about cystic fibrosis and potentially improve treatment options for others in the future. The study is currently recruiting participants of all genders, ages ranging from 18 to 26 years old and 14 to 609 years old.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Heterozygote or homozygote patients with cystic fibrosis with normal routine pre bronchodilator spirometry including normal FEV1(L), FVC(L) and FEV1/FVC%.
- • Exclusion Criteria:Heterozygote or homozygote patients with cystic fibrosis with ABNORMAL routine pre bronchodilator spirometry
- • -
About Gelb, Arthur F., M.D.
Dr. Arthur F. Gelb, M.D., is a distinguished clinical trial sponsor with extensive experience in advancing medical research and improving patient outcomes. With a strong background in clinical medicine and a commitment to innovation, Dr. Gelb leads trials that focus on developing new therapies and interventions across various therapeutic areas. His dedication to rigorous scientific methodology and ethical standards ensures that all studies conducted under his sponsorship are designed to deliver reliable and impactful results. Dr. Gelb's leadership fosters collaboration among multidisciplinary teams, enhancing the potential for breakthroughs that can significantly benefit patient care and treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lakewood, California, United States
Long Beach, California, United States
Patients applied
Trial Officials
Arthur Gelb, MD
Principal Investigator
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials